Submit Deal

VECTORY

Summary

A biotech company dedicated to developing transformative medicines for people with neurodegenerative diseases using cutting-edge science and technologies.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 113 M

Avg. Deal Size£ 113 M

Market Context

Senior Management

Sander van Deventer
CEO
Michael Wyzga
CFO
Elena Ritsou
CCO

Sort

vectory

HQ - Netherlands

Biotechnology

13 Nov 2023

Investment Date

£ 112 M

Deal Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy